Manhattan Scientifics Announces Initiation of Coverage by Independent Equity Research Firm SeeThruEquity, LLC
October 01 2013 - 09:30AM
Business Wire
Manhattan Scientifics Inc. (OTCQB: MHTX) announced today that
SeeThruEquity, LLC has initiated coverage on the Company. The
report is now available for viewing at the following link.
“We initiate coverage on Manhattan Scientifics, Inc. (“MSI”)
with a price target of $0.14 per share. MSI is focused on
technology transfer and the commercialization of transformative
technologies in the nanotechnology space. MSI is currently focused
on two opportunities, one in nanostructured metals technology
through wholly-owned subsidiary Metallicum Inc., and the other in
nanoparticle based cancer detection through wholly owned subsidiary
Senior Scientific LLC. With one licensing deal already in place,
others in negotiation on the metals technology side of the business
and commencement of product trials on their cancer detection
product slated for 2014, MSI has numerous revenue drivers and
catalysts through the 2014-2015 timeframe,” remarked Ajay Tandon,
Director of Research at SeeThruEquity, LLC.
About SeeThruEquity
SeeThruEquity, LLC is an investment research and corporate
access firm that produces high quality research reports on smallcap
and microcap companies with less than $1 billion in market
capitalization. The research is unbiased and not paid-for research.
These companies have typically been underserved by the traditional
Wall Street analyst establishment. We are unfettered by any ties to
investment banking or trading, and distribute our high impact
research as an approved contributor on Thomson Reuters One (First
Call), CapitalIQ, FactSet, Zacks and StockTwits, as well as to our
own audience of investors from our corporate website. We also
contribute our financial estimates on companies in our research
coverage universe to Thomson Estimates (commonly referred to as
consensus or consensus estimates on the Street).
For more information, visit http://www.seethruequity.com.
The investment opinions expressed are solely those of
SeeThruEquity, LLC. SeeThruEquity, LLC has not been compensated for
the preparation of the report on the Company by any third party or
the Company.Forward-looking statement. This press release contains
forward-looking statements, which are subject to a number of risks,
assumptions and uncertainties that could cause the Company's actual
results to differ materially from those projected in such
forward-looking statements. Management at Manhattan Scientifics
Inc. believes that purchase of its shares should be considered to
be at the high end of the risk spectrum. Forward-looking statements
speak only as of the date made and are not guarantees of future
performance. We undertake no obligation to publicly update or
revise any forward-looking statements.
Manhattan Scientifics, Inc. PR & IRMarvin Maslow,
917-923-3300Email: marvin@mhtx.comorCorporate
Advisory/PRFastnet Advisors:Anthony Furey, 631-665-1234Email:
mailto:mtfurey@fastnetadvisors.comorHawk Associates:Frank Hawkins,
305-451-1888Email: f.hawkins@hawkassociates.comorEuropean
Contact:Herbert Strauss, +43-316-296-316Email: herbert "at"
eu-ir.comorAnalyst:Research SeeThruEquity, LLCAjay Tandon,
646-495-0939Co-Founder and Director
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Mar 2023 to Mar 2024